alltype fastplex kit all-fast11lx (Thermo Fisher)
Thermo Fisher is a verified supplier 
Thermo Fisher manufactures this product 
90
Structured Review
Thermo Fisher
alltype fastplex kit all-fast11lx
Alltype Fastplex Kit All Fast11lx, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alltype+fastplex+kit+all-fast11lx/alltype+fastplex+kit+all+fast11lx/pm37460756-254-7-11
Average 90 stars, based on 1 article reviews
Alltype Fastplex Kit All Fast11lx, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alltype+fastplex+kit+all-fast11lx/alltype+fastplex+kit+all+fast11lx/pm37460756-254-7-11
Average 90 stars, based on 1 article reviews
alltype fastplex kit all-fast11lx - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Next-Generation Sequencing:Article Title: SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial. Article Snippet: Despite advances, few therapeutics have shown efficacy in severe coronavirus disease 2019 (COVID-19).. In a different context, virus-specific T cells have proven safe and effective.. We conducted a randomized (2:1), open-label, phase 1/2 trial to evaluate the safety and efficacy of off-the-shelf, partially human leukocyte antigen (HLA)-matched, convalescent donorderived severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)specific T cells (CoV-2-STs) in combination with standard of care (SoC) in patients with severe COVID-19 compared to SoC during Delta variant predominance. Immunopeptidomics:Article Title: SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial. Article Snippet: Despite advances, few therapeutics have shown efficacy in severe coronavirus disease 2019 (COVID-19).. In a different context, virus-specific T cells have proven safe and effective.. We conducted a randomized (2:1), open-label, phase 1/2 trial to evaluate the safety and efficacy of off-the-shelf, partially human leukocyte antigen (HLA)-matched, convalescent donorderived severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)specific T cells (CoV-2-STs) in combination with standard of care (SoC) in patients with severe COVID-19 compared to SoC during Delta variant predominance. Sequencing:Article Title: SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial. Article Snippet: Despite advances, few therapeutics have shown efficacy in severe coronavirus disease 2019 (COVID-19).. In a different context, virus-specific T cells have proven safe and effective.. We conducted a randomized (2:1), open-label, phase 1/2 trial to evaluate the safety and efficacy of off-the-shelf, partially human leukocyte antigen (HLA)-matched, convalescent donorderived severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)specific T cells (CoV-2-STs) in combination with standard of care (SoC) in patients with severe COVID-19 compared to SoC during Delta variant predominance. |